Neuroelectrics
Neuroelectrics develops personalized brain monitoring and stimulation technologies for treating neurological disorders through cloud-based neuromodulation. The company's Starstim platform integrates a wireless headpiece for EEG monitoring and multi-channel transcranial Electrical Stimulation (tES), cloud-based secure remote treatment delivery, and personalization protocols based on neuroscience research and patient…
Funding snapshot
About
Neuroelectrics develops personalized brain monitoring and stimulation technologies for treating neurological disorders through cloud-based neuromodulation. The company's Starstim platform integrates a wireless headpiece for EEG monitoring and multi-channel transcranial Electrical Stimulation (tES), cloud-based secure remote treatment delivery, and personalization protocols based on neuroscience research and patient physiological data. Neuroelectrics is conducting a pivotal trial in refractory focal epilepsy and a pilot study in at-home treatment of depression. The platform is also used by hundreds of researchers with hundreds of published papers. Founded in 2011 and headquartered in Barcelona, Spain, the company has raised approximately $17.9M in Series A funding. Neuroelectrics differentiates itself through its novel neurocircuit therapeutics approach that identifies dysfunctional neural networks and targets them holistically, offering a non-invasive, non-drug option for patients whose conditions have not been controlled by medications or surgery.
Business model
Brain Computer Interface > Applications > Healthcare > Therapeutics,
Wearable Technology > Health and Wellness Devices > Mental Wellness,
Disease Self Management > Neurological Disorders > Monitoring > Psychological Health > Device > Wearable,
Fitness & Wellness Tech > Mind & Body Wellness > Stress Management > Devices,
Healthcare IT > Provider > Clinical Operations > Decision Support > Diagnosis > Differential Diagnosis > Electrodiagnostics > Cardiology,
Neurology > Medical Devices > Therapeutic Devices > Psychiatric,
MassChallenge Batches > HealthTech > 2017
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.